Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Praluent
| Field | Information |
|---|---|
| Medication Name | Praluent |
| Generic Name | Alirocumab |
| Purpose | Used to lower LDL cholesterol levels in adults with primary hyperlipidemia (high cholesterol) or mixed dyslipidemia, as well as to reduce the risk of heart attack, stroke, and certain heart procedures in adults with established cardiovascular disease. |
| Mechanism of Action | PCSK9 inhibitor that lowers LDL cholesterol by preventing PCSK9 from binding to LDL receptors, increasing the number of LDL receptors available to clear LDL cholesterol from the blood. |
| Dosage Forms | Subcutaneous injection |
| Available Strengths | 75 mg/mL, 150 mg/mL |
| Dosage Frequency | Every 2 weeks or once a month, as directed by a healthcare provider |
| Common Side Effects | Injection site reactions (redness, itching, swelling, pain), flu-like symptoms, nasopharyngitis (common cold) |
| Serious Side Effects | Allergic reactions (rash, itching, swelling, difficulty breathing), serious injection site reactions |
| Drug Interactions | Statins (may increase the risk of muscle problems) |
| Important Notes | Administer subcutaneously; rotate injection sites. Store in the refrigerator and protect from light. |
| Storage | Store in the refrigerator (36°F to 46°F or 2°C to 8°C) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Inject the missed dose as soon as you remember, then resume your regular schedule. |
| Alternatives | Repatha (evolocumab), Leqvio (inclisiran), Statins (atorvastatin, rosuvastatin), Zetia (Ezetimibe) |
Praluent Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Repatha (evolocumab) | PCSK9 inhibitor | Similar mechanism of action to Praluent; administered via subcutaneous injection. |
| Leqvio (inclisiran) | siRNA that reduces PCSK9 synthesis | Administered via subcutaneous injection twice per year. |
| Atorvastatin (Lipitor) | HMG-CoA reductase inhibitor (statin) | Reduces cholesterol production in the liver. A common first-line treatment. |
| Ezetimibe (Zetia) | Cholesterol absorption inhibitor | Reduces cholesterol absorption in the small intestine. Often used in combination with statins. |
Praluent Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Injection site reactions (redness, itching, swelling, pain) | Allergic reactions (rash, itching, swelling, difficulty breathing) |
| Flu-like symptoms | Serious injection site reactions (severe pain, prolonged redness, infection) |
Praluent Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Primary Hyperlipidemia or Mixed Dyslipidemia | 75 mg every 2 weeks or 300 mg once a month | May be adjusted to 150 mg every 2 weeks based on LDL-C response | Administer subcutaneously in the thigh, abdomen, or upper arm. Rotate injection sites. |
| Established Cardiovascular Disease (to reduce risk of cardiovascular events) | 75 mg every 2 weeks or 300 mg once a month | May be adjusted to 150 mg every 2 weeks based on LDL-C response | Administer subcutaneously in the thigh, abdomen, or upper arm. Rotate injection sites. |
